Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
US8409573B2 · kind B2 · utility
6Cited by
1References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 14, 2006 |
| Grant date | Apr 2, 2013 |
| Priority date | — |
| Expiry date | Jun 19, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.